Skip to main content
United gains access to PAH drug in Arena deal

United Therapeutics has agreed to pay $800 million upfront to Arena Pharmaceuticals in exchange for worldwide rights to the latter's ralinepag for pulmonary arterial hypertension, which is being tested in a late-stage trial. Aside from royalties from sales, Arena could receive $150 million if the drug gains approval from a key non-US market and $250 million if the inhaled version of the medication gains FDA approval.

Full Story: